Published in J Cell Sci on August 25, 2009
The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther (2012) 1.12
Pituitary tumor transforming gene binding factor: a new gene in breast cancer. Cancer Res (2010) 1.02
New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci (2015) 0.94
Proto-oncogene PBF/PTTG1IP regulates thyroid cell growth and represses radioiodide treatment. Cancer Res (2011) 0.90
Fifteen years' experience in thyroid surgery. Ann R Coll Surg Engl (2010) 0.87
Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors. J Clin Endocrinol Metab (2013) 0.87
The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells. Endocrinology (2014) 0.84
Microarray analysis of genes associated with cell surface NIS protein levels in breast cancer. BMC Res Notes (2011) 0.82
Association between sodium iodide symporter and differentiated Thyroid cancer: a meta-analysis of 9 studies. Int J Clin Exp Med (2015) 0.77
Modulation of sodium iodide symporter in thyroid cancer. Horm Cancer (2014) 0.77
Cancer: Novel target to enhance radioiodine uptake in thyroid cancer. Nat Rev Endocrinol (2013) 0.77
On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2010) 0.77
Pro-invasive Effect of Proto-oncogene PBF Is Modulated by an Interaction with Cortactin. J Clin Endocrinol Metab (2016) 0.75
Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer. Oncogene (2017) 0.75
Functional consequences of the first reported mutations of the proto-oncogene PTTG1IP/PBF. Endocr Relat Cancer (2017) 0.75
Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab (2001) 4.73
Culture of hormone-dependent functional epithelial cells from rat thyroids. Proc Natl Acad Sci U S A (1980) 4.39
The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev (2003) 3.48
Tetraspanins as regulators of protein trafficking. Traffic (2006) 1.98
Cloning of the human sodium lodide symporter. Biochem Biophys Res Commun (1996) 1.87
Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab (2003) 1.73
Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab (1999) 1.67
Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer (2006) 1.66
Sodium iodide symporter: a novel strategy to target breast, prostate, and other cancers? Lancet (2003) 1.56
Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology (1997) 1.45
Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem (2001) 1.40
An immunohistochemical study of Na+/I- symporter in human thyroid tissues and salivary gland tissues. Endocrinology (1998) 1.34
Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology (1997) 1.32
Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab (2003) 1.24
Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab (2001) 1.17
Anion selectivity by the sodium iodide symporter. Endocrinology (2003) 1.16
Regulation of the 26S proteasome by adenovirus E1A. EMBO J (2000) 1.09
Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun (1997) 1.09
A novel binding factor facilitates nuclear translocation and transcriptional activation function of the pituitary tumor-transforming gene product. J Biol Chem (2000) 1.08
Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab (1998) 1.08
Molecular analysis of a congenital iodide transport defect: G543E impairs maturation and trafficking of the Na+/I- symporter. Mol Endocrinol (2005) 1.06
The Q267E mutation in the sodium/iodide symporter (NIS) causes congenital iodide transport defect (ITD) by decreasing the NIS turnover number. J Cell Sci (2004) 1.02
Na(+)-I- symport activity is present in membrane vesicles from thyrotropin-deprived non-I(-)-transporting cultured thyroid cells. Proc Natl Acad Sci U S A (1994) 1.01
Transforming events in thyroid tumorigenesis and their association with follicular lesions. J Clin Endocrinol Metab (2001) 1.00
Na+/I- symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab (1998) 0.99
Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest (1998) 0.99
Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis. J Clin Endocrinol Metab (2005) 0.98
Low expression of sodium iodide symporter identifies aggressive thyroid tumors. Cancer Lett (2003) 0.96
Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer. J Endocrinol (1999) 0.96
PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer. BMC Cancer (2007) 0.96
Development of monoclonal antibodies against the human sodium iodide symporter: immunohistochemical characterization of this protein in thyroid cells. J Clin Endocrinol Metab (1999) 0.95
Monocarboxylate transporter 8 in neuronal cell growth. Endocrinology (2008) 0.94
Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas. Thyroid (2000) 0.92
Cloning of a novel human putative type Ia integral membrane protein mapping to 21q22.3. Genomics (1998) 0.92
Identification of in vivo phosphorylation sites and their functional significance in the sodium iodide symporter. J Biol Chem (2007) 0.89
Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer. J Clin Endocrinol Metab (2006) 0.89
PTTG and PBF repress the human sodium iodide symporter. Oncogene (2007) 0.88
Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas. J Clin Endocrinol Metab (2003) 0.87
Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod Pathol (2001) 0.87
Cell surface targeting accounts for the difference in iodide uptake activity between human Na+/I- symporter and rat Na+/I- symporter. J Clin Endocrinol Metab (2005) 0.87
Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors. Am J Pathol (2004) 0.86
Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid (1999) 0.85
Semi-quantitative comparison of the differentiation markers and sodium iodide symporter messenger ribonucleic acids in papillary thyroid carcinomas using RT-PCR. Eur J Endocrinol (2000) 0.84
Development of reverse transcription-competitive polymerase chain reaction method to quantitate the expression levels of human sodium iodide symporter. Thyroid (1999) 0.81
Functional characterization of human thyroid tissue with immunohistochemistry. Thyroid (2007) 0.81
Expression of cAMP response element-binding protein and sodium iodide symporter in benign non-functioning and malignant thyroid tumours. Eur J Endocrinol (2003) 0.81
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature (2003) 13.00
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA (2004) 8.12
Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA (2010) 5.20
Iodine status of UK schoolgirls: a cross-sectional survey. Lancet (2011) 4.96
Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes (2004) 4.81
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med (2012) 4.59
Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med (2010) 3.24
Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin Endocrinol (Oxf) (2007) 3.17
Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf) (2014) 2.56
Iodine supplementation for pregnancy and lactation-United States and Canada: recommendations of the American Thyroid Association. Thyroid (2006) 2.56
Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med (2012) 2.24
Thyrotoxicosis. Lancet (2012) 2.22
Parameters for reliable results in genetic association studies in common disease. Nat Genet (2002) 2.00
Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature (2010) 1.70
A single nucleotide polymorphism in the CD40 gene on chromosome 20q (GD-2) provides no evidence for susceptibility to Graves' disease in UK Caucasians. Clin Endocrinol (Oxf) (2004) 1.64
Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study. J Am Coll Cardiol (2006) 1.59
Seven newly identified loci for autoimmune thyroid disease. Hum Mol Genet (2012) 1.57
Novel truncating thyroglobulin gene mutations associated with congenital hypothyroidism. Endocrine (2013) 1.51
Regulation of DNA-end resection by hnRNPU-like proteins promotes DNA double-strand break signaling and repair. Mol Cell (2012) 1.50
Association of the TSHR gene with Graves' disease: the first disease specific locus. Eur J Hum Genet (2005) 1.49
Mapping between Visual Analogue Scale and Standard Gamble data; results from the UK Health Utilities Index 2 valuation survey. Health Econ (2006) 1.49
Regression mapping of association between the human leukocyte antigen region and Graves disease. Am J Hum Genet (2004) 1.47
Childhood weight gain and thyroid autoimmunity at age 60-64 years: the 1946 British birth cohort study. J Clin Endocrinol Metab (2013) 1.45
Treatment of Graves' disease with antithyroid drugs: current perspectives. Thyroid (2010) 1.44
A comparative quality assessment of evidence-based clinical guidelines in endocrinology. Clin Endocrinol (Oxf) (2013) 1.42
Cardiovascular abnormalities in hyperthyroidism. Am J Med (2005) 1.38
Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics (2010) 1.37
131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab (2006) 1.35
A novel and major association of HLA-C in Graves' disease that eclipses the classical HLA-DRB1 effect. Hum Mol Genet (2007) 1.35
Prevalence of subclinical thyroid dysfunction and its relation to socioeconomic deprivation in the elderly: a community-based cross-sectional survey. J Clin Endocrinol Metab (2006) 1.30
Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease. Hum Mol Genet (2009) 1.26
Adenovirus 12 E4orf6 inhibits ATR activation by promoting TOPBP1 degradation. Proc Natl Acad Sci U S A (2010) 1.17
Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene (2005) 1.14
A role for E1B-AP5 in ATR signaling pathways during adenovirus infection. J Virol (2008) 1.11
Factors influencing the ability of nuclear localization sequence peptides to enhance nonviral gene delivery. Bioconjug Chem (2004) 1.10
Oxidative stress and dysregulation of the taurine transporter in high-glucose-exposed human Schwann cells: implications for pathogenesis of diabetic neuropathy. Am J Physiol Endocrinol Metab (2009) 1.08
Recruitment of CBP/p300, TATA-binding protein, and S8 to distinct regions at the N terminus of adenovirus E1A. J Virol (2005) 1.08
Mediator of DNA damage checkpoint 1 (MDC1) regulates mitotic progression. J Biol Chem (2009) 1.08
Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro. Diabetes (2002) 1.07
Thyroid dyshormonogenesis is mainly caused by TPO mutations in consanguineous community. Clin Endocrinol (Oxf) (2013) 1.05
Association of PTPN22 haplotypes with Graves' disease. J Clin Endocrinol Metab (2006) 1.05
Sphingosine 1-phosphate receptor expression profile and regulation of migration in human thyroid cancer cells. Biochem J (2006) 1.03
Epigenetic control of a VDR-governed feed-forward loop that regulates p21(waf1/cip1) expression and function in non-malignant prostate cells. Nucleic Acids Res (2010) 1.03
Pituitary tumor transforming gene binding factor: a new gene in breast cancer. Cancer Res (2010) 1.02
Modified cell cycle status in a mouse model of altered neuronal vulnerability (slow Wallerian degeneration; Wlds). Genome Biol (2008) 1.02
Transcriptional control by adenovirus E1A conserved region 3 via p300/CBP. Nucleic Acids Res (2009) 1.01
Roles for APIS and the 20S proteasome in adenovirus E1A-dependent transcription. EMBO J (2006) 1.01
Pituitary tumor-transforming gene and its binding factor in endocrine cancer. Expert Rev Mol Med (2010) 1.01
Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21 329 person-years of follow-up. J Clin Endocrinol Metab (2014) 1.00
Differential regulation of lipogenesis and leptin production by independent signaling pathways and rosiglitazone during human adipocyte differentiation. Diabetes (2003) 0.99
Polymorphism of the CTLA-4 gene is associated with autoimmune hypothyroidism in the United Kingdom. Thyroid (2002) 0.98
Serotype-specific inactivation of the cellular DNA damage response during adenovirus infection. J Virol (2010) 0.98
Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis. J Clin Endocrinol Metab (2005) 0.98
Identification of a second CtBP binding site in adenovirus type 5 E1A conserved region 3. J Virol (2008) 0.96
Delivery of siRNA mediated by histidine-containing reducible polycations. J Control Release (2008) 0.96
Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion. Carcinogenesis (2010) 0.95
Hyperthyroidism and cardiovascular morbidity and mortality. Thyroid (2002) 0.95
Early expression of thyroid hormone deiodinases and receptors in human fetal cerebral cortex. Brain Res Dev Brain Res (2002) 0.92
The relationship between serum TSH and free T4 in older people. J Clin Pathol (2012) 0.92
Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit. Pharmacoeconomics (2010) 0.91
Expression and function of the novel proto-oncogene PBF in thyroid cancer: a new target for augmenting radioiodine uptake. J Endocrinol (2011) 0.91
Recruitment of NCOR1 to VDR target genes is enhanced in prostate cancer cells and associates with altered DNA methylation patterns. Carcinogenesis (2012) 0.91
Thyroid stimulating hormone receptor (TSHR) intron 1 variants are major risk factors for Graves' disease in three European Caucasian cohorts. PLoS One (2010) 0.90
Adenovirus E1A interacts directly with, and regulates the level of expression of, the immunoproteasome component MECL1. Virology (2011) 0.90
Proto-oncogene PBF/PTTG1IP regulates thyroid cell growth and represses radioiodide treatment. Cancer Res (2011) 0.90
The interaction of the hnRNP family member E1B-AP5 with p53. FEBS Lett (2005) 0.89
One Base Deletion (c.2422delT) in the TPO Gene Causes Severe Congenital Hypothyroidism. J Clin Res Pediatr Endocrinol (2014) 0.89
Identification of a second independent binding site for the pCAF acetyltransferase in adenovirus E1A. Virology (2009) 0.89
TSHR is the main causative locus in autosomal recessively inherited thyroid dysgenesis. J Pediatr Endocrinol Metab (2012) 0.88
Glucocorticoid regulation of p450 aromatase activity in human adipose tissue: gender and site differences. J Clin Endocrinol Metab (2002) 0.88
Adenovirus E4orf3 targets transcriptional intermediary factor 1γ for proteasome-dependent degradation during infection. J Virol (2011) 0.88
Patient information in Graves' disease and thyroid-associated ophthalmopathy: readability assessment of online resources. Thyroid (2013) 0.88
Role for Wee1 in inhibition of G2-to-M transition through the cooperation of distinct human papillomavirus type 1 E4 proteins. J Virol (2006) 0.87
Detection and surgical treatment of cervical lymph nodes in differentiated thyroid cancer. Thyroid (2006) 0.87
The targeting of the proteasomal regulatory subunit S2 by adenovirus E1A causes inhibition of proteasomal activity and increased p53 expression. J Biol Chem (2004) 0.87
The human IL-3/granulocyte-macrophage colony-stimulating factor locus is epigenetically silent in immature thymocytes and is progressively activated during T cell development. J Immunol (2010) 0.87